BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9375899)

  • 1. Treatment of Paget's disease of bone with intravenous pamidronate: comparison of 2 different modes of treatment.
    Ismail AA; Fox P; Stamp TC; Dhillon V; Crisp AJ; MacGregor A
    J Rheumatol; 1997 Nov; 24(11):2266-7. PubMed ID: 9375899
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of remission of Paget's disease of bone.
    Patel S; Stone MD; Coupland C; Hosking DJ
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
    Arboleya L; Sánchez J; Iglesias G; Arranz JL
    Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of intravenous pamidronate in Paget's disease of bone.
    Grauer A; Klar B; Scharla SH; Zieglar R
    Semin Arthritis Rheum; 1994 Feb; 23(4):283-4. PubMed ID: 8009261
    [No Abstract]   [Full Text] [Related]  

  • 6. Pamidronate infusions for the treatment of Paget's disease of bone.
    Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
    Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous aminopropylidene bisphosphonate in the treatment of severe polyostotic Paget's disease of bone.
    Fritz P; Lioté F; Kuntz D
    Semin Arthritis Rheum; 1994 Feb; 23(4):282. PubMed ID: 8009260
    [No Abstract]   [Full Text] [Related]  

  • 8. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paget's disease of bone: presentation, extent and response to bisphosphonates.
    Wang LM; Au-Yeong ML; McKenna MJ
    Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous aminopropylidene bisphosphonate in patients with refractory Paget's disease.
    Cormier C; Hilliquin P; Menkès CJ
    Br J Rheumatol; 1993 Aug; 32(8):767-8. PubMed ID: 8348290
    [No Abstract]   [Full Text] [Related]  

  • 11. Response of biochemical markers of bone turnover to pamidronate infusion in Paget's disease of bone.
    Sharp CA; Worsfold M; Rowlands PR; Davie MW
    Semin Arthritis Rheum; 1994 Feb; 23(4):242-3. PubMed ID: 8009239
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonate resistance in Paget's disease of bone.
    Joshua F; Epstein M; Major G
    Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Paget's disease of bone with single dose intravenous pamidronate.
    Watts RA; Skingle SJ; Bhambhani MM; Pountain G; Crisp AJ
    Ann Rheum Dis; 1993 Aug; 52(8):616-8. PubMed ID: 8215628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous pamidronate in Paget's disease--response is dependent on radiographic and biochemical severity.
    Stuckey BG; Gutteridge DH; Stewart GO; Prince RL; Ward LC; Kent GN; Prince RI; Retallack RW; Bhagat CI; Nicholson GC
    Semin Arthritis Rheum; 1994 Feb; 23(4):286. PubMed ID: 8009263
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of the bisphosphonate space in treatment and retreatment of Paget's disease.
    Stone MD; Patel S; Hosking DJ
    Semin Arthritis Rheum; 1994 Feb; 23(4):278. PubMed ID: 8009256
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Paget's bone disease with the bisphosphonate APD.
    Mautalen CA
    Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of intravenous pamidronate therapy on Paget's disease of bone.
    Bombassei GJ; Yocono M; Raisz LG
    Am J Med Sci; 1994 Oct; 308(4):226-33. PubMed ID: 7942981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.